contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


patient-data-from-the-extension-part-of-alzinovas-phase-1b-study-with-alz-101-is-being-processed

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Alzinova is a biotechnology company. The company specializes in the therapeutic treatment of Alzheimer's and conducts research and development of peptides that are further developed as vaccines. In addition, the company also develops various research tools in the work area. The largest operations are in the Nordic market. The company was founded in 2011 and is headquartered in Gothenburg. 

Alzinova

Alzinova AB (publ) (ticker: ALZ), a Swedish biopharmaceutical company focused on the development of treatments for Alzheimer's disease, announces today that patient data from the extension part...

<div class="mfn-preamble"><p><strong>Alzinova AB (publ) (ticker: ALZ), a Swedish biopharmaceutical company focused on the development of treatments for Alzheimer's disease, announces today that patient data from the extension part of the Phase 1b study is now being processed. Alzinova is processing data collected up to week 42 of the extension part, i.e. patients have been in the phase 1b study for at least 84 weeks.</strong></p></div><div class="mfn-body"><ul><li>Data collection for the 42-week analysis of the extension part of the phase 1b study is now complete.</li><li>Results from the 42-week analysis are expected to be published in late November - December 2024.</li></ul><p><em>“The 42-week analysis in the extension part of our phase 1b study is an important step forward. We look forward to analysing and communicating the results, which will provide us with valuable insights into the long-term safety and efficacy of the vaccine. These data will be central to the planning of our upcoming phase 2 study and our efforts to apply for a Fast Track designation with the FDA. It is also very pleasing to note the great interest in our ongoing study and upcoming results from the major pharmaceutical companies during last week's BIO Europe conference in Stockholm”, </em>says Tord Labuda, CEO of Alzinova AB.</p><p>Alzinova is conducting a multi-arm phase 1b study with the vaccine candidate ALZ-101. The company has previously announced that it intends to analyse data collected up to week 42 of the extension arm, i.e. when patients have participated in the phase 1b study for at least 84 weeks. The results of the data analysis from the collected data are now being processed and are expected to be published in late November - December 2024.</p><p><strong>About ALZ-101</strong><br>ALZ-101 is a therapeutic vaccine that targets toxic accumulations of amyloid-beta oligomers in the brain. This is different from other treatments that focus on larger plaques, which can contain both harmful and harmless proteins. By vaccinating with ALZ-101, the body is expected to generate its own antibodies against the harmful oligomers, which can protect the brain's synapses and potentially slow the progression of Alzheimer's disease. Over the past year, Alzinova has reported promising results from the ongoing phase 1b study, indicating a potential positive effect of the drug candidate ALZ-101 in patients with early Alzheimer's disease.</p><p><strong>For more information, please contact:</strong><br>Tord Labuda, CEO<br>E-mail: tord.labuda@alzinova.com</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/e25c190f-2964-46a4-8c8c-8e62ca9c0700/patient-data-from-the-extension-part-of-alzinovas-phase-1b-study-with-alz-101-is-being-processed.pdf" class="mfn-generated mfn-primary">Patient data from the extension part of Alzinova's phase 1b study with ALZ-101 is being processed</a></p></div>

Patient data from the extension part of Alzinova's phase 1b study with ALZ-101 is being processed

Wall Streetin arvostustasoihin verrattuna Eurooppakin näyttää nyt houkuttelevalta

Federal Reserven korkopäätös: Kiire loppui tähän

Lääkekehityssijoittaminen: Arvonluonti yrityskaupoilla ja lisensointisopimuksilla

EKP:n korkopäätös: Keskuspankki ilman rajoitteita

Euroalueen ostopäälliköt: Onks sen jälkeen vielä mäki?

Pysy ajantasalla Inderesin uutiskirjeillä